Home Hyperhomocysteinemia, DNA methylation and vascular disease
Article
Licensed
Unlicensed Requires Authentication

Hyperhomocysteinemia, DNA methylation and vascular disease

  • Md S. Jamaluddin , Xiaofeng Yang and Hong Wang
Published/Copyright: December 8, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 12

Abstract

Hyperhomocysteinemia (HHcy) has been established as a potent independent risk factor for cardiovascular disease (CVD) and the underlying mechanism is largely unknown. We were the first to propose that hypomethylation is the key biochemical mechanism by which homocysteine (Hcy) inhibits endothelial cell (EC) growth. We reported that clinically relevant concentrations of Hcy (10–50 μmol/L) exerts highly selective inhibitory effects on cyclin A transcription and EC growth through a hypomethylation related mechanism, which blocks cell cycle progression and endothelium regeneration. Recently, we demonstrated that Hcy reduces DNA methyltransferase 1 (DNMT1) activity and demethylates cyclin A promoter leading to cyclin A chromatin remodeling. We found that adenovirus-transduced DNMT1 gene expression reverses the inhibitory effect of Hcy on cyclin A expression and EC growth inhibition. We hypothesize that DNA hypomethylation is a key biochemical mechanism responsible for Hcy-induced cyclin A suppression and growth inhibition in EC and contributes to CVD.

Clin Chem Lab Med 2007;45:1660–6.


Corresponding author: Hong Wang, Department of Pharmacology, Temple University School of Medicine, 3420 North Broad Street, Philadelphia, PA 19140, USA Phone: +1-215-707-5986, Fax: +1-215-707-7068,

Received: 2007-8-6
Accepted: 2007-10-2
Published Online: 2007-12-08
Published in Print: 2007-12-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Homocysteine research: alive and kicking!
  2. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis
  3. Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention trial
  4. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients
  5. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases
  6. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review
  7. Biomarkers of folate and vitamin B12 status in cerebrospinal fluid
  8. The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis – a systematic review
  9. Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review
  10. Homocysteine, left ventricular dysfunction and coronary artery disease: is there a link?
  11. Hyperhomocysteinemia and high-density lipoprotein metabolism in cardiovascular disease
  12. Hyperhomocysteinemia, DNA methylation and vascular disease
  13. Measuring subclinical atherosclerosis: is homocysteine relevant?
  14. Plasma protein homocysteinylation in uremia
  15. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease
  16. Hyperhomocysteinemia – association with renal transsulfuration and redox signaling in rats
  17. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine
  18. Defects in homocysteine metabolism: diversity among hyperhomocyst(e)inemias
  19. The molecular basis of homocysteine thiolactone-mediated vascular disease
  20. Importance of folate-homocysteine homeostasis during early embryonic development
  21. Association between homocysteine, vitamin B6 concentrations and inflammation
  22. Quantitative profiling of folate and one-carbon metabolism in large-scale epidemiological studies by mass spectrometry
  23. Holotranscobalamin in laboratory diagnosis of cobalamin deficiency compared to total cobalamin and methylmalonic acid
  24. Haptocorrin in humans
  25. Small ubiquitin-like modifier-1 (SUMO-1) modification of thymidylate synthase and dihydrofolate reductase
  26. Decreased p66Shc promoter methylation in patients with end-stage renal disease
  27. Synergism between AT1 receptor and hyperhomocysteinemia during vascular remodeling
  28. Differential expression of γ-aminobutyric acid receptor A (GABAA) and effects of homocysteine
  29. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial
  30. Acknowledgement
  31. Contents, Volume 45, 2007
  32. Author Index
  33. Subject Index
Downloaded on 17.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.350/html
Scroll to top button